On March 29th 2019, the UK becomes a “third country” from the EU, and will transition to a new relationship. The impact of Brexit on the pharmaceutical industry continues to evolve, but UK companies who develop or supply product for sale or clinical use in the EU/EEA will likely face regulatory complexity, added costs, disruption in their supply of raw materials and finished-goods, and risk long-term loss of revenue and customers.
The European Medicines Agency (EMA) is currently headquartered in London, but as a consequence of Brexit will be transitioning to a new home in Amsterdam by January 2019. Post-Brexit, slower marketing approval of drugs in the UK is expected regardless of what deal, if any, is implemented. The UK government is hoping to retain an arrangement almost identical to the current situation for drug approvals. However, the European Union has indicated they will not accept such an arrangement following the departure of the UK from the union. With uncertainty remaining over the final state, as well as the likelihood of a final agreement that is inferior to the current state, it is unsurprising that drug approval and regulatory issues are posing major concerns for pharmaceutical companies.
What we know so far is that, after March 29th 2019, the following will occur:
• Marketing Authorisation (MA) holders, if held in UK, will have to be transferred to an EU or EEA country.
• Each consignment of UK-manufactured Active Pharmaceutical Ingredients (APIs) to the EU/EEA needs to be accompanied by an MHRA certificate of conformation to EU GMPs.
• Each batch of drug product will need to be released by a QP within the EU/EEA.
• Pharmacovigilance will need to be managed from a location within the EU/EEA.
• There will no longer be unrestricted transport of goods between the EU and the UK.
• Expect added paperwork, transport delays, and likely customs duties.
HiTech Health has developed a range of strategies to enable healthcare companies to successfully navigate Brexit. Our support will be tailored to your company’s needs. Please email us at info@hitech-health.com to request further information on the range of services we can provide.
Recent News
Breakthrough Gene Therapy Becomes First to Slow Progression of Huntington’s Disease
UK researchers said on Wednesday they have slowed the progression of the fatal neural condition Huntington's disease for the first time with a groundbreaking new gene therapy. Huntington's disease causes nerve cells in the brain to decay over time. The disease affects...
Wholesale Distribution Authorisation (WDA): What is a WDA and why is it important?
Pharmaceutical and biotechnology companies are required to comply with strict regulations to ensure medicines are safe and effective. One key requirement for wholesaling activities is the Wholesale Distribution Authorisation (WDA). In the EU and UK, all wholesale...
ATMP Sector Spotlight: H1 2025 Review
The HiTech Health team has reviewed recent developments in the Advanced Therapeutic Medicinal Product (ATMP) sector during the first half of 2025. Below are some key updates from the industry so far: Sector Summary: In Europe, the ATMP sector is on track to...
Stay Up To Date
Connect with us to receive the latest HiTech Health and industry updates.